A listed North American firm needed support with the identification of early-stage in-licensing or acquisition opportunities in the highly competitive field of regenerative medicine. Alacrita was engaged to perform the search.


We conducted a scouting exercise for late-stage academic or seed-/early-stage commercial programs in the field of regenerative stem cell therapies. By leveraging our extensive network in academia and early-stage private companies, we were able to introduce our client to a number of opportunities that were not previously known to them nor were they yet listed in syndicated licensing databases. The client then conducted its own detailed assessment of these opportunities.